Evaluation of the Safety and Immunogenicity of M-M-RII (Combination Measles-mumps-rubella Vaccine): Clinical Trials of Healthy Children and Adults Published Between 2010 and 2019.

Autor: Nyaku M; From the Merck & Co., Inc., Kenilworth, New Jersey., Richardson E; From the Merck & Co., Inc., Kenilworth, New Jersey., Martinon-Torres F; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario and Universidad de Santiago de Compostela (USC), Galicia, Spain.; Genetics, Vaccines, and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), Galicia, Spain., Kuter BJ; From the Merck & Co., Inc., Kenilworth, New Jersey.

Publikováno v: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2021 Nov 01; Vol. 40 (11), pp. 1046-1054.

Infectious hepatitis (hepatitis A) research in nonhuman primates.

Autor: Hilleman MR, Provost PJ, Villarejos VM, Buynak EB, Miller WJ, Ittensohn OL, Wolanski BS, McAleer WJ

Publikováno v: Bulletin of the Pan American Health Organization [Bull Pan Am Health Organ] 1977; Vol. 11 (2), pp. 140-52.

[Use and effectiveness of multiple vaccines of life viruses].

Autor: Villarejos VM

Publikováno v: Boletin de la Oficina Sanitaria Panamericana. Pan American Sanitary Bureau [Bol Oficina Sanit Panam] 1975 Feb; Vol. 78 (2), pp. 132-7.

Clinical and laboratory studies of live attenuated RA 27/3 and HPV 77-DE rubella virus vaccines.

Autor: Weibel RE, Villarejos VM, Klein EB, Buynak EB, McLean AA, Hilleman MR

Publikováno v: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) [Proc Soc Exp Biol Med] 1980 Oct; Vol. 165 (1), pp. 44-9.

Practical aspects concerning combined live viral vaccines.

Autor: Hielleman MR, Weibel RE, Buynak EB, Villarejos VM

Publikováno v: Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis [Schweiz Rundsch Med Prax] 1975 Jan 28; Vol. 64 (4), pp. 98-108.